Deciphering the biology that drives response to immunotherapy
|
|
- Josephine Curtis
- 5 years ago
- Views:
Transcription
1 Deciphering the biology that drives response to immunotherapy Phenoptics TM Quantitative Pathology Platform Trent Norris, Field Application Scientist September 15, 2016 HUMAN HEALTH ENVIRONMENTAL HEALTH 2014 PerkinElmer
2 Triple Negative Breast Cancer Survivor My Aunt Full Remission Since 2014
3 Triple-negative breast cancer: Range of histology. Clifford A. Hudis, and Luca Gianni The Oncologist 2011;16: by AlphaMed Press
4 Triple-negative breast cancer: Recurrence and survival. Clifford A. Hudis, and Luca Gianni The Oncologist 2011;16: by AlphaMed Press
5 Cancer Immunotherapy is providing lasting benefits Personalized immunotherapy is the future Anti-PD1s Leading the way The immune system is the agent that improves outcome and cures people with metastatic solid cancer.
6 Immuno-oncology is not yet personalized PD-L1 IHC helps pick out responders, But PD-L1 but negatives response for positives averages 40% also respond, thus making test of little use
7
8 The biology that drives response is a lot more complicated Response depends on specific cell-to-cell interactions
9 Cell-to-cell signaling - markers of interest
10 Melanoma example, conventional PD-L1 IHC How can we characterize cell-to-cell interactions with IHC?
11 Making immunohistochemistry precise and quantitative Visual Protein Assessment Quantitative, multi-analyte, per-cell needs new imaging and staining methods The tissue is the issue Still the gold standard primary diagnosis and most directly connected to disease Information not presently being accessed with conventional approaches Samples are getting smaller and less available
12 Phenoptics Quantitative Pathology Solutions Reagents Instruments Software Services Opal multiplexed immunofluorescence staining kits and protocols Vectra Automated Quantitative Pathology Imaging Systems (6-slide and 200-slide) Mantra Quantitative Pathology Workstation inform Tissue Finder advanced image analysis & phenotyping software TIBCO Spotfire multivariate analytics and data analysis Full workflow services: Method development Slide staining and scanning Data analysis Assay transfer
13 Reagents: Sequential application of colors TSA enables use of multiple antibodies raised in the same species in the same tissue section (or even the same cell compartment) MW Tissue section Antigen A Antigen B Antigen C Antibody A (Rabbit) Antibody B (Rabbit) Antibody C (Rabbit) HRP-conjugated Anti-Rabbit IgG or Superpicture Fluorochrome tyramide
14 Advantages of Opal TM 1. Select antibodies based on performance, not species 2. TSA enables 1. Amplifies the signal so camera exposures of 10s of ms vs 100s or 1000s 1. Key for automated scanning, and for clinical workflow 2. Ease of balanced signals goal of factors of 2 or 3 for best unmixing 3. Reduce photobleaching can scan slides multiple times with <10% reduction in signal 3. Can multiplex up to 6 markers, possibly increasing in the future. 4. Less use of expensive antibodies because of high signal:noise 5. Assay optimization is faster & more predictable than conventional multicolor indirect immunofluorescence (weeks versus months)
15 Melanoma example, conventional PD-L1 IHC
16 Phenoptics multiplexed IHC - Opal red = PD-L1 yellow = CD8 green = Foxp3 magenta = CD20 aqua = sox10 pink = CD163 blue = DAPI
17 Analyzing samples stained w/ many colors Multiplexed stained samples are difficult to interpret Colors blend together and are difficult to resolve Expression patterns are hidden by colocalization Visual assessment is qualitative at best Autofluorescence is also present in FFPE samples Solution: Multispectral imaging separates multiple markers trainable pattern recognition automates segmentation of images into tumor and stroma, collects per cell data for phenotyping, retains spatial distribution information Monochrome Color (RGB) Multispectral
18 Viewing 10x whole slide views in Phenochart
19 Simulated IHC views for Opal TIL kit applied to breast cancer CD4 Opal520 CD20 Opal540 CD8 Opal570 Foxp3 Opal620 CD68 Opal650 CK Opal690 DAPI Spectrally separated H&E view Foxp3 view Cytokeratin view CD68 view CD20 view CD8 view CD4 view
20 inform learn-by-example interface
21 inform learn-by-example interface
22 inform learn-by-example interface
23 inform learn-by-example interface
24 Phenoptics multiplexed IHC - Opal red = PD-L1 yellow = CD8 green = Foxp3 magenta = CD20 aqua = sox10 pink = CD163 blue = DAPI
25 Phenoptics multiplexed IHC - Opal With tumor detection and cell phenotyping Tissue segmentation red = tumor PD-L1 green = stroma yellow blue=background = CD8 green = Foxp3 red = PD-L1+ tumor cell magenta aqua = PD-L1- = tumor CD20 cell green = regulatory T cell aqua sox10 yellow = cytotoxic T cell pink magenta = CD163 = B cell pink = macrophage blue DAPI Phenotyping blue = other
26 Example of Quantifying PDL1
27 Example #1 PD-L1 simulated IHC
28 Example #1 PD-L1 scoring Tissue segmentation red = tumor green = stroma blue=background Scoring blue = 0+ yellow = 1+ orange = 2+ red = 3+
29 Phenoptics multiplexed IHC - Opal red = PD-L1 yellow = CD8 green = Foxp3 magenta = CD20 aqua = sox10 pink = CD163 blue = DAPI
30 Breast Cancer Example Dr. Beth Mittendorf, MD Anderson
31 Case #1 pseudo composite cyan = CK purple = killer T cell green = helper T cell red = B cell orange = PD-L1 yellow = Foxp3
32 Case #1 inform tumor-stroma and cell phenotype maps Phenotype Counts Tumor 4,380 Phenotypes tumor killer T helper T T-reg B cell other Killer T 146 Helper T 640 Regulator T 156 B cell 208 Other 2,500 Total 9,260
33 Case #1 - Spatial point pattern analysis in R (example calc.) 33% of tumor cells have a killer T cell within 25 microns distance
34 Case #2 with tumor / stroma map and cell phenotypes Phenotype Counts Tumor 1,810 Phenotypes tumor killer T helper T T-reg B cell other Killer T 213 Helper T 0 Regulator T 14 B cell 1,270 Other 2,160 Total 6,467
35 Case #3 with tumor / stroma map and cell phenotypes Phenotype Counts Tumor 4,630 Phenotypes tumor killer T helper T T-reg B cell other Killer T 1,070 Helper T 962 Regulator T 236 B cell 80 Other 1,230 Total 8,206
36 Case #4 with tumor / stroma map and cell phenotypes Phenotype Counts Tumor 3,620 Phenotypes tumor killer T helper T T-reg B cell other Killer T 203 Helper T 285 Regulator T 127 B cell 218 Other 1,850 Total 6,307
37 Case #5 with tumor / stroma map and cell phenotypes Phenotype Counts Tumor Phenotypes tumor killer T helper T T-reg B cell other Killer T 2,570 Helper T 1,670 Regulator T 192 B cell 61 Other 1,540 Total 8,968
38 From strong interaction to weak 61% 41% 33% 3%
39
40 AE
41 Tissue Map Filter Settings merged_cell_seg_data - Slide ID: (FIHC4_Multi_11)
42 Scatter plots and Histograms
43 Future directions laying groundwork for clinical use Digital pathology workflows Autostaining Fluorescence whole slide Simulated IHC region selection multiplex analysis 20x whole slide image hematoxylin and DAB Future developments under QSR Slide analysis times getting significantly shorter Developing protocols for Bond Rx Process time for 7-color assay approx. 14 hours Today Field Level Analysis Phenotype Spatial / R-scripts Informatics Solutions Case Level Analysis Case Study Level Analysis
44 PD-1 Blockade with Pembrolizumab in Advanced Merkel Cell Carcinoma Merkel cell carcinoma 56% response with Merck Pembro viral status, mutation burden, PDL1 IHC, CD8 infiltration, not predictive Phenoptics revealed immunobiology consistent with anti-pd1 MOA. Potential basis of a predictive test
45 Novel quantitative multiplexed PD1/PDL1 IHC test provides superior prediction to treatment response in melanoma patients Conv. PDL1 IHC has a PPV of ~30% Multiplexed IF PPV 79%, NPV 83%
46 I think we are making progress! What do you think? Questions? red = PD-L1 yellow = CD8 green = Foxp3 magenta = CD20 aqua = sox10 pink = CD163 blue = DAPI
47 We re all in it to win it together! Thank you Trenton Norris
Immune Cell Phenotyping in Solid Tumors using Quantitative Pathology
Immune Cell Phenotyping in Solid Tumors using Quantitative Pathology James R. Mansfield Director of Quantitative Pathology Applications 2009 PerkinElmer What is Quantitative Pathology? Quantitative Pathology
More informationUntangling the tumor microenvironment
Webinar Series Untangling the tumor microenvironment Illuminating the complex interactions & functions of immune cells December 10, 2014 Instructions for Viewers To share webinar via social media: To share
More informationNext-Gen Analytics in Digital Pathology
Next-Gen Analytics in Digital Pathology Cliff Hoyt, CTO Cambridge Research & Instrumentation April 29, 2010 Seeing life in a new light 1 Digital Pathology Today Acquisition, storage, dissemination, remote
More informationAbstract. Background. Objective
Molecular epidemiology of clinical tissues with multi-parameter IHC Poster 237 J Ruan 1, T Hope 1, J Rheinhardt 2, D Wang 2, R Levenson 1, T Nielsen 3, H Gardner 2, C Hoyt 1 1 CRi, Woburn, Massachusetts,
More informationInterpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment. Lorcan Sherry, CSO OracleBio
Interpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment Lorcan Sherry, CSO OracleBio Company Overview OracleBio is a specialised CRO providing
More informationImmunotherapy in NSCLC Pathologist role
Immunotherapy in NSCLC Pathologist role Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in NSCLC Khono et al, Trans Lung
More informationWelcome. Nanostring Immuno-Oncology Summit. September 21st, FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
Welcome Nanostring Immuno-Oncology Summit September 21st, 2017 1 FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. Agenda 4:00-4:30
More informationMultiplex immunofluorescence for investigating the prognostic value of immune cells Chidozie Anyaegbu, PhD
Multiplex immunofluorescence for investigating the prognostic value of immune cells Chidozie Anyaegbu, PhD Catholic Health Australia Symposium Mater Hospital, Brisbane 1 st June 2018 Why colorectal cancer?
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationSingle and Multiplex Immunohistochemistry
Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch
More informationResults you can trust
PRODUCT I NF OR MAT ION pharmdx Results you can trust The first and only FDA-approved PD-L1 test to assess the magnitude of treatment effect on progression-free survival in melanoma patients from OPDIVO
More informationWorkflow. Connecting the Pieces For Total Patient Care
Workflow Connecting the Pieces For Total Patient Care Biocare provides a full line of IHC and molecular pathology products for cancer and infectious disease diagnosis. From a full range of equipment: including
More informationGetting the Whole Picture for Immuno-Oncology Therapies
Joseph Krueger, Chief Scientific Officer, Flagship Biosciences, Inc. Getting the Whole Picture for Immuno-Oncology Therapies Key concepts: Immuno-oncology (IO) therapies have changed the way we think about
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationBreast Cancer Interpretation Guide
Breast Cancer Interpretation Guide UCT D O R P NEW ERBB2/ C E P S ht e ZytoLig lor Prob o C l a u 2D D17S12 ng to the i d r o c c a ting for re-tes idelines 2013 ASCO Gu Breast Cancer Interpretation Guide
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationNext-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry
Nat Met, April 2014 Nat Med, April 2014 Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry Journal Club Timo Böge Overview Introduction Conventional Immunohistochemistry
More informationAgilent companion diagnostics for cancer immunotherapy
Agilent companion diagnostics for cancer immunotherapy Annika Eklund, PhD Global Product Manager Companion Diagnostics Agilent Technologies Aalborg 1 Agilent Trusted Answers. Together OUR FOCUS life sciences,
More informationIn Situ Hybridization: Market Strategies and Forecasts, US,
In Situ Hybridization: Market Strategies and Forecasts, US, 2018-2024 Table of Contents In Situ Hybridization: Executive Summary The study is designed to give a comprehensive overview of the In Situ Hybridization
More informationLayered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue
Page 1 The need for multiplex detection of tissue biomarkers. There is a constant and growing demand for increased biomarker analysis in human tissue specimens. Analysis of tissue biomarkers is key to
More informationNature Methods: doi: /nmeth Supplementary Figure 1
Supplementary Figure 1 Finite-element analysis of cell cluster dynamics in different cluster trap architectures. (a) Cluster-Chip (b) Filter (c) A structure identical to the Cluster-Chip except that one
More informationPredictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -
Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al - Lukas Bubendorf Pathology Improved overall survival as a result of combination therapy Predictive biomarkers for the treatment
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationComprehensive Tumor Profiling of Immune Response and Systems Biology. HTG EdgeSeq Immuno-Oncology Assay. HTG EdgeSeq Oncology Biomarker Panel
Comprehensive Tumor Profiling of Immune Response and Systems Biology HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Oncology Biomarker Panel A new frontier in the research of cancer therapeutics HTG provides
More informationPD-L1 and Immunotherapy of GI cancers: What do you need to know
None. PD-L1 and Immunotherapy of GI cancers: What do you need to know Rondell P. Graham September 3, 2017 2017 MFMER slide-2 Disclosure No conflicts of interest to disclose 2017 MFMER slide-3 Objectives
More informationSpatially resolved multiparametric single cell analysis. Technical Journal Club 19th September 2017 Christina Müller (Group Speck)
Spatially resolved multiparametric single cell analysis Technical Journal Club 19th September 2017 Christina Müller (Group Speck) Why spatially resolved multiparametric single cell analysis? Multiparametric
More informationHER2 FISH pharmdx TM Interpretation Guide - Breast Cancer
P A T H O L O G Y HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer For In Vitro Diagnostic Use FDA approved as an aid in the assessment of patients for whom Herceptin TM (trastuzumab) treatment
More informationBiomarker strategy for Personalized Healthcare at Roche
Biomarker strategy for Personalized Healthcare at Roche E mi l i a An d e r sso n o n b e h a l f o f t h e I R I S t e a m No v 2 0 1 6 6th Munich Biomarker Conference Nov 29th 30th, 2016 Ramada Hotel
More informationONCOSEC ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS
ONCOSEC TM ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS 0 Forward Looking Statements Our commentary and responses to your questions may contain forward looking statements, as described in the
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationInterleukin-2 Single Agent and Combinations
Interleukin-2 Single Agent and Combinations Michael K Wong MD PhD Norris Cancer Center University of Southern California mike.wong@med.usc.edu Disclosures Advisory Board Attendance Merck Bristol Myers
More informationStergios Moschos, MD
Stergios Moschos, MD Clinical Associate Professor of Medicine Department of Medicine Division of Hematology/Oncology University of North Carolina at Chapel Hill Solid Tumor with one of the Highest Mutation
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationReview of NEO Testing Platforms. Lawrence M. Weiss, MD Medical Director, Aliso Viejo
Review of NEO Testing Platforms Lawrence M. Weiss, MD Medical Director, Aliso Viejo Lawrence Weiss, M.D. Medical Director, Aliso Viejo Dr. Weiss currently serves as NeoGenomics Medical Director, Aliso
More informationFluorescence Microscopy
Fluorescence Microscopy Imaging Organelles Mitochondria Lysosomes Nuclei Endoplasmic Reticulum Plasma Membrane F-Actin AAT Bioquest Introduction: Organelle-Selective Stains Organelles are tiny, specialized
More informationIncorporating pharmacodynamic, response and patient selection biomarkers. Paul Elvin PhD Chief Translational Science Officer Aptus Clinical
Incorporating pharmacodynamic, response and patient selection biomarkers Paul Elvin PhD Chief Translational Science Officer Aptus Clinical 22 Oncology drug development Biomarkers key for: Strong hypothesis
More informationImmune Microenvironment in Microsatellite- Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters
Biology of Human Tumors Immune Microenvironment in Microsatellite- Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters Janelle B. Pakish 1, Qian Zhang 1, Zhongyuan Chen 2, Han Liang 3,
More informationSupplementary Online Content
Supplementary Online Content Gaule P, Smithy JW, Toki M, et al. A quantitative comparison of antibodies to PD-L1. JAMA Oncol. Published online August 18, 2016. doi:10.1001/jamaoncol.2016.3015. efigure
More informationWHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example
WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example YIDOU ZHANG Health Economics and Payer Analytics Director Oncology Payer Evidence and Pricing, AstraZeneca
More informationSupplementary Online Content
Supplementary Online Content Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologistbased assessment of 4 immunohistochemistry assays for PD-L1 expression in non small cell lung
More informationImmuno-Oncology: Perspectives on Current Therapies & Future Developments
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/immuno-oncology-perspectives-currenttherapies-future-developments/9502/
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationTargeting the Tumor Locally
ARMING THE IMMUNE SYSTEM TO FIGHT CANCER Targeting the Tumor Locally October 2017 NASDAQ:ONCS Cautionary Note Regarding Forward-Looking Statements To the extent statements contained in the following presentations
More informationThe Role of Immuno-Oncology Biomarkers in Lung Cancer
The Role of Immuno-Oncology Biomarkers in Lung Cancer Vamsidhar Velcheti, MD, FACP Staff Physician, Associate Director Center for Immuno-Oncology Research Taussig Cancer Institute Cleveland Clinic November
More informationGaining New Insights Through IF Multiplexed Staining and Analysis. Tyna Hope, Ph.D. P.Eng Biomarker Imaging Research Laboratory October 5, 2017
Gaining New Insights Through IF Multiplexed Staining and Analysis Tyna Hope, Ph.D. P.Eng Biomarker Imaging Research Laboratory Assessing more from Tissue Sections Gaps with More Common Methods Most common
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationMoving Forward with Immunotherapies for Cancer
A Virtual Think Tank Executive Summary Moving Forward with Immunotherapies for Cancer By: Barbara Gilmore, Senior Consultant, Transformational Health, Frost & Sullivan Frost & Sullivan recently invited
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationDISCOVER MORE WITH LESS SAMPLE. nanostring.com/3d
nanostring.com/3d DISCOVER MORE WITH LESS SAMPLE. WHY COMPROMISE? ncounter Vantage ASSAYS POWERED BY 3D BIOLOGY TECHNOLOGY Don t let sample volume limit your analytical aspirations. Quantify DNA, RNA,
More informationGeisinger Clinic Annual Progress Report: 2011 Nonformula Grant
Geisinger Clinic Annual Progress Report: 2011 Nonformula Grant Reporting Period July 1, 2012 June 30, 2013 Nonformula Grant Overview The Geisinger Clinic received $1,000,000 in nonformula funds for the
More informationVernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we
9e avondsymposium: "Nieuwe ontwikkelingen in de behandeling van NSCLC" 9 november 2016, UMCG Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we Wim Timens Professor and Chair
More informationPosters and Presentations
Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationChallenges for use of CTCs as a Diagnostic. Farideh Z. Bischoff, Ph.D. Interim CSO Sr. Director, Translational Clinical Development Biocept, Inc.
Challenges for use of CTCs as a Diagnostic Farideh Z. ischoff, Ph.D. Interim CSO Sr. Director, Translational Clinical Development iocept, Inc. Current Technology for CTC Testing Existing CTC testing platform
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationSupplemental figure 1. PDGFRα is expressed dominantly by stromal cells surrounding mammary ducts and alveoli. A) IHC staining of PDGFRα in
Supplemental figure 1. PDGFRα is expressed dominantly by stromal cells surrounding mammary ducts and alveoli. A) IHC staining of PDGFRα in nulliparous (left panel) and InvD6 mouse mammary glands (right
More informationQIAGEN's Growing Immuno-Oncology Testing Portfolio
QIAGEN's Growing Immuno-Oncology Testing Portfolio QIAGEN Your Partner in Translational Medicine Current Biomarkers of Immuno-Oncology Focus: Immuno-Oncology Testing Portfolio Tumor mutation burden (TMB)
More informationVisual interpretation in pathology
13 Visual interpretation in pathology Tissue architecture (alteration) evaluation e.g., for grading prostate cancer Immunohistochemistry (IHC) staining scoring e.g., HER2 in breast cancer (companion diagnostic
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationAnti-PD-L1 antibody [28-8] ab205921
Anti-PD-L1 antibody [28-8] ab205921 2 Abreviews 16 References 15 Images Overview Product name Anti-PD-L1 antibody [28-8] Description Tested applications Species reactivity Immunogen Rabbit monoclonal [28-8]
More informationHighlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationInternational Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting
International Society of Breast Pathology USCAP 2017 Annual Meeting Immune Targeting in Breast Cancer Ashley Cimino-Mathews, MD Assistant Professor of Pathology and Oncology The Johns Hopkins Hospital
More informationThree Hours Thirty Minutes
INTERPRETATION HER2 IQFISH pharmdx TM Interpretation Guide Three Hours Thirty Minutes it s about time Breast carcinoma (FFPE) stained with HER2 IQFISH pharmdx Gastric cancer (FFPE) stained with HER2 IQFISH
More informationNew Biological and Immunological Therapies for Cancer
New Biological and Immunological Therapies for Cancer Sant P. Chawla, M.D., FRACP The Sarcoma Oncology Center, Santa Monica CA 90403 7 th International Conference on Drug Discovery &Therapy 1 Promising
More informationPD-L1 Analyte Control DR
Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1
More informationDOUBLE STAINS. Toll-Free: Direct:
DOUBLE STAINS CD61 + CD71 DAB Brown: CD61 Alk. Phos. Red: CD71 Bone Marrow DAB Brown: Megakaryocytes Alk. Phos. Red: Erythroid Precursors 400x CD61 (2f2) 0.1 ml concentrate............. 161M-14 0.5 ml
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More information1 + denotes a higher variable value for the deletion or depletion than the control scenario; - denotes a lower value.
Table S1. Significant changes in granuloma variables at 200 days post-infection for deletion and depletion of combinations of two individual TNF activities versus the baseline control scenario 1. Sample
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationThe Power of Predictive Quantitative Tissue-Based Diagnostics in Cancer Immunotherapy
The Power of Predictive Quantitative Tissue-Based Diagnostics in Cancer Immunotherapy The American Society of Clinical Oncology named Immunotherapy 2.0 Advance of the Year at its 2017 Annual Meeting in
More informationThe PD-1 pathway of T cell exhaustion
The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1
More informationImmunotherapy for Breast Cancer Clinical Development
Immunotherapy for Breast Cancer Clinical Development Laurence Buisseret, MD, PhD Breast Cancer Translational Research Laboratory Institut Jules Bordet Université Libre de Bruxelles (ULB) ESMO preceptorship
More informationLIST OF ORGANS FOR HISTOPATHOLOGICAL ANALYSIS:!! Neural!!!!!!Respiratory:! Brain : Cerebrum,!!! Lungs and trachea! Olfactory, Cerebellum!!!!Other:!
LIST OF ORGANS FOR HISTOPATHOLOGICAL ANALYSIS:!! Neural!!!!!!Respiratory:! Brain : Cerebrum,!!! Lungs and trachea! Olfactory, Cerebellum!!!!Other:! Spinal cord and peripheral nerves! Eyes, Inner ear, nasal
More informationInterpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma. PD-L1 IHC 22C3 pharmdx is FDA-approved for in vitro diagnostic use
Interpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma PD-L1 IHC 22C3 pharmdx is FDA-approved for in vitro diagnostic use For countries outside of the United States, see the local
More informationSupplementary Figure 1. Double-staining immunofluorescence analysis of invasive colon and breast cancers. Specimens from invasive ductal breast
Supplementary Figure 1. Double-staining immunofluorescence analysis of invasive colon and breast cancers. Specimens from invasive ductal breast carcinoma (a) and colon adenocarcinoma (b) were staining
More informationESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY
ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune
More informationAdvances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
More informationOncology Drug Development Using Molecular Pathology
Oncology Drug Development Using Molecular Pathology Introduction PRESENTERS Lee Schacter, PhD, MD, FACP Executive Medical Director, Oncology Clinipace Worldwide Martha Bonino Director, Strategic Accounts
More informationMy name is Dr. David Ilson, Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, New York.
Welcome to this CME/CE-certified activity entitled, Integrating the Latest Advances Into Clinical Experience: Data and Expert Insights From the 2016 Meeting on Gastrointestinal Cancers in San Francisco.
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationThe following slides were presented at the TIGA Workshop, and are enclosed in the PP show format (*.pps) in order to include all presented details.
Disclaimer: The following slides were presented at the TIGA Workshop, and are enclosed in the PP show format (*.pps) in order to include all presented details. These slides are proprietary and should not
More informationAssessment Run C1 2017
Assessment Run C1 2017 PD-L1 The first assessment in this new NordiQC Companion module C1 focused on the accuracy of the PD-L1 IHC assays performed by the participating laboratories to identify patients
More informationIT S ABOUT TIME. IQFISH pharmdx Interpretation Guide THREEHOURSTHIRTYMINUTES. HER2 IQFISH pharmdxtm. TOP2A IQFISH pharmdxtm
I N T E R P R E TAT I O N IQFISH pharmdx Interpretation Guide TM HER2 IQFISH pharmdxtm TOP2A IQFISH pharmdxtm Breast carcinoma (FFPE) stained with HER2 IQFISH pharmdx Breast carcinoma (FFPE) stained with
More informationDCVax Novel Personalized Immunotherapies for Solid Tumors
DCVax Novel Personalized Immunotherapies for Solid Tumors Phaciliate Immunotherapy World Forum January 26, 2016 Disclaimer Certain statements made in this presentation are forward-looking statements of
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationPathology of Inflammatory Breast Cancer (IBC) A rare tumor
Pathology of Inflammatory Breast Cancer (IBC) A rare tumor Jelle Wesseling 1, John Martens 2, Gabe Sonke 1, Carolien Schröder 3 1: Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam
More informationA NEW VISION IN THE DIAGNOSTIC/PROGNOSIS OF CANCER USING QUANTITATIVE. Prof. Antonio Ferrer-Montiel
A NEW VISION IN THE DIAGNOSTIC/PROGNOSIS OF CANCER USING QUANTITATIVE BIOLOGY Prof. Antonio Ferrer-Montiel QUANTITATIVE BIOLOGY: A NECESSITY Objective measures Quantitative ranking Subjective bias elimination
More informationEnhanced Cancer Vaccine Effectiveness with NKTR-214, a CD122-Biased Cytokine
Enhanced Cancer Vaccine Effectiveness with NKTR-214, a CD122-Biased Cytokine Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics SMI Cancer Vaccines, September 2017 Nektar Therapeutics
More informationThermo Scientific UltraVision Quanto for Immunohistochemistry The New Generation Micro-Polymer Detection System
Thermo Scientific for Immunohistochemistry The New Generation Micro-Polymer Detection System highest sensitivity sharp crisp clear shorter incubation times UltraVision Quanto the new Micro-Polymer System
More information